# OnCo record nct04589845 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04589845/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04589845", "NCT04589845" ;
  schema:name "Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study"@en ;
  schema:alternateName "TAPISTRY"@en ;
  schema:description "A phase 2 trial of Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine and Inavolisib in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04589845/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04589845> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2021-01-18" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/inavolisib/>, <https://onco.cc/drugs/camonsertib/> ;
  onco:companies <https://onco.cc/companies/flatiron-health/> .